FY2024 EPS Forecast for scPharmaceuticals Reduced by Analyst

scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Equities researchers at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of scPharmaceuticals in a research note issued to investors on Monday, March 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($1.44) per share for the year, down from their prior forecast of ($1.43). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for scPharmaceuticals' current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for scPharmaceuticals' Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS and FY2026 earnings at ($0.36) EPS.

Separately, Craig Hallum decreased their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, November 14th.

scPharmaceuticals Trading Down 1.4 %

NASDAQ SCPH traded down $0.04 on Thursday, reaching $2.89. The company had a trading volume of 988,976 shares, compared to its average volume of 318,779. The stock has a market cap of $144.62 million, a price-to-earnings ratio of -1.52 and a beta of 0.40. The stock's 50 day moving average is $3.37 and its 200-day moving average is $3.91. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. scPharmaceuticals has a 52 week low of $2.76 and a 52 week high of $6.20.

Remove Ads

Institutional Investors Weigh In On scPharmaceuticals

Several large investors have recently modified their holdings of the business. Rubric Capital Management LP grew its position in shares of scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company's stock valued at $21,774,000 after purchasing an additional 1,250,000 shares during the period. AIGH Capital Management LLC lifted its stake in scPharmaceuticals by 1.2% in the fourth quarter. AIGH Capital Management LLC now owns 4,174,367 shares of the company's stock valued at $14,777,000 after buying an additional 50,000 shares in the last quarter. King Luther Capital Management Corp boosted its holdings in shares of scPharmaceuticals by 28.4% in the fourth quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company's stock valued at $10,117,000 after buying an additional 632,120 shares during the period. Suvretta Capital Management LLC bought a new position in scPharmaceuticals during the 3rd quarter worth about $9,343,000. Finally, Thrivent Financial for Lutherans raised its position in scPharmaceuticals by 1.4% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company's stock valued at $4,783,000 after buying an additional 14,866 shares during the last quarter. 89.52% of the stock is currently owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.